D. Frye

2.5k total citations · 2 hit papers
22 papers, 1.9k citations indexed

About

D. Frye is a scholar working on Oncology, Cancer Research and Dermatology. According to data from OpenAlex, D. Frye has authored 22 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 12 papers in Cancer Research and 5 papers in Dermatology. Recurrent topics in D. Frye's work include Cancer Treatment and Pharmacology (17 papers), Breast Cancer Treatment Studies (12 papers) and Chemotherapy-related skin toxicity (5 papers). D. Frye is often cited by papers focused on Cancer Treatment and Pharmacology (17 papers), Breast Cancer Treatment Studies (12 papers) and Chemotherapy-related skin toxicity (5 papers). D. Frye collaborates with scholars based in United States and United Kingdom. D. Frye's co-authors include Aman U. Buzdar, Gabriel N. Hortobágyi, Terry L. Smith, L. D. Ziegler, Frankie A. Holmes, G. N. Hortobágyi, A. U. Buzdar, R S Walters, R. Theriault and Martin N. Raber and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

D. Frye

22 papers receiving 1.9k citations

Hit Papers

Phase II Trial of Taxol, an Active Drug in the Treatment ... 1991 2026 2002 2014 1991 1996 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Phase II Trial of Taxol, an Active Drug in the Treatment of Metastatic Breast Cancer
    1991 615 citations Frankie A. Holmes, R S Walters et al. JNCI Journal of the National Cancer Institute profile →
  2. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer.
    1996 596 citations Gabriel N. Hortobágyi, Terry L. Smith et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
D. Frye United States 12 1.5k 708 401 304 197 22 1.9k
Giuseppe Capri Italy 27 2.1k 1.4× 717 1.0× 453 1.1× 555 1.8× 396 2.0× 77 2.8k
G. N. Hortobágyi United States 23 1.7k 1.2× 962 1.4× 543 1.4× 573 1.9× 323 1.6× 106 2.7k
Cecilia Nisticò Italy 23 1.2k 0.8× 555 0.8× 403 1.0× 306 1.0× 142 0.7× 70 1.6k
G. Catimel France 21 1.3k 0.9× 339 0.5× 395 1.0× 521 1.7× 70 0.4× 45 1.7k
A. U. Buzdar United States 18 1.2k 0.8× 930 1.3× 299 0.7× 379 1.2× 60 0.3× 46 2.1k
R. Theriault United States 13 970 0.7× 439 0.6× 162 0.4× 264 0.9× 75 0.4× 25 1.3k
Robert J. Belt United States 20 1.5k 1.0× 386 0.5× 459 1.1× 789 2.6× 204 1.0× 59 2.6k
Paola Papaldo Italy 25 1.1k 0.7× 439 0.6× 336 0.8× 411 1.4× 107 0.5× 66 1.7k
Gisele Sarosy United States 21 810 0.5× 231 0.3× 225 0.6× 654 2.2× 108 0.5× 38 1.7k
Linnea Chap United States 13 1.0k 0.7× 417 0.6× 367 0.9× 662 2.2× 131 0.7× 28 1.7k

Countries citing papers authored by D. Frye

Since Specialization
Citations

This map shows the geographic impact of D. Frye's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. Frye with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. Frye more than expected).

Fields of papers citing papers by D. Frye

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. Frye. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. Frye. The network helps show where D. Frye may publish in the future.

Co-authorship network of co-authors of D. Frye

This figure shows the co-authorship network connecting the top 25 collaborators of D. Frye. A scholar is included among the top collaborators of D. Frye based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. Frye. D. Frye is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mazouni, Chafika, Shu‐Wan Kau, D. Frye, et al.. (2007). Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers. Annals of Oncology. 18(5). 874–880. 57 indexed citations
2.
Hanrahan, Emer O., D. Frye, Aman U. Buzdar, et al.. (2005). Twelve-year follow-up of a randomized trial of high-dose chemotherapy (HDC) and autologous hematopoietic stem cell support (ASCS) for high-risk primary breast carcinoma. Journal of Clinical Oncology. 23(16_suppl). 663–663. 3 indexed citations
3.
González-Angulo, Ana M., Shu‐Wan Kau, Kristine Broglio, et al.. (2004). Invasive lobular carcinoma (ILC) “classic type”: Distinct clinical features. Journal of Clinical Oncology. 22(14_suppl). 663–663. 4 indexed citations
4.
González-Angulo, Ana M., Shu‐Wan Kau, Aman U. Buzdar, et al.. (2004). Invasive lobular carcinoma (ILC) “classic type”: Distinct clinical features. Journal of Clinical Oncology. 22(14_suppl). 663–663. 2 indexed citations
5.
Holmes, Frankie A., Vicente Valero, R S Walters, et al.. (1999). Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: Phase I results. Annals of Oncology. 10(4). 403–411. 14 indexed citations
6.
Frye, D., et al.. (1999). Capecitabine: nursing implications of a new oral chemotherapeutic agent.. PubMed. 26(4). 753–62. 38 indexed citations
7.
Valero, V., Zaid Abdel Rahman, D. Frye, et al.. (1998). Clinical course of breast cancer patients with metastases confined to the lungs treated with chemotherapy. Annals of Oncology. 9(4). 413–418. 28 indexed citations
8.
9.
Rahman, Zaid Abdel, R. Champlin, Gabriela Rondón, et al.. (1997). Phase I/II study of dose-intense doxorubicin/paclitaxel/cyclophosphamide with peripheral blood progenitor cells and cytokine support in patients with metastatic breast cancer.. PubMed. 24(5 Suppl 17). S17–77. 10 indexed citations
10.
Hortobágyi, Gabriel N., et al.. (1996). Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer.. Journal of Clinical Oncology. 14(8). 2197–2205. 596 indexed citations breakdown →
11.
12.
Buzdar, Aman U., Gabriel N. Hortobágyi, D. Frye, & Vicente Valero. (1996). Second-line chemotherapy for metastatic breast cancer including quality of life issues. The Breast. 5(4). 312–317. 7 indexed citations
13.
Buzdar, A. U., G. N. Hortobágyi, D. Frye, et al.. (1994). Bioequivalence of 20-mg once-daily tamoxifen relative to 10-mg twice-daily tamoxifen regimens for breast cancer.. Journal of Clinical Oncology. 12(1). 50–54. 11 indexed citations
14.
Holmes, Frankie A., Vicente Valero, Ronald S. Walters, et al.. (1993). The M. D. Anderson Cancer Center experience with Taxol in metastatic breast cancer.. PubMed. 161–9. 45 indexed citations
15.
Holmes, Frankie A., R S Walters, R. Theriault, et al.. (1991). Phase II Trial of Taxol, an Active Drug in the Treatment of Metastatic Breast Cancer. JNCI Journal of the National Cancer Institute. 83(24). 1797–1805. 615 indexed citations breakdown →
16.
Ziegler, L. D., et al.. (1991). Lack of correlation between histologic findings and response to chemotherapy in metastatic breast cancer. Cancer. 68(3). 628–633. 5 indexed citations
17.
Hortobágyi, Gabriel N., Richard L. Theriault, D. Frye, et al.. (1990). Pirarubicin in Combination Chemotherapy for Metastatic Breast Cancer. American Journal of Clinical Oncology. 13. S54–S54. 4 indexed citations
18.
Hortobágyi, Gabriel N., D. Frye, Aman U. Buzdar, et al.. (1989). Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma. Cancer. 63(1). 37–45. 149 indexed citations
19.
Hortobágyi, Gabriel N., Gerald P. Bodey, Aman U. Buzdar, et al.. (1987). Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: a prospective randomized study.. Journal of Clinical Oncology. 5(3). 354–364. 102 indexed citations
20.
Hortobagyi, G. N., D. Frye, Frankie A. Holmes, et al.. (1987). Phase II study of iproplatin in metastatic breast carcinoma.. PubMed. 71(12). 1193–6. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Giuseppe Capri Breakdown of academic impact, for papers by G. N. Hortobágyi Breakdown of academic impact, for papers by Cecilia Nisticò Breakdown of academic impact, for papers by G. Catimel Breakdown of academic impact, for papers by A. U. Buzdar Breakdown of academic impact, for papers by R. Theriault Breakdown of academic impact, for papers by Robert J. Belt Breakdown of academic impact, for papers by Paola Papaldo Breakdown of academic impact, for papers by Gisele Sarosy Breakdown of academic impact, for papers by Linnea Chap
Rankless by CCL
2026